Sagimet Biosciences Inc. gets a Buy rating as denifanstat targets MASH & acne; key Phase 3 catalysts and funding risks ahead.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results